Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Inks Deal to Distribute Grifols Immunohematology Products

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Spanish healthcare and biopharmaceutical manufacturing firm Grifols today announced a deal with Novartis Diagnostics to commercialize certain Grifols products in the US.

Following regulatory approval in the US, the Novartis business would market and distribute Grifols' immunohematology instruments, assays, and other products, under the terms of the deal. Novartis will also market and distribute semi-automated, pre-transfusion diagnostic products made by subsidiaries of Grifols and Progenika blood group antigen genotyping products that are currently distributed by Grifols.

During the summer, Grifols and Progenika partnered on a distribution deal covering Progenika's microchip blood typing technology called Bloodchip.

Financial and other terms of today's agreement were not disclosed.

In a statement, Grifols, based in Barcelona, Spain, said that Novartis will help strengthen its position in the US. It added that currently more than 80 percent of the US blood supply is tested on Novartis' testing platforms, which were co-developed with molecular diagnostics firm Gen-Probe.

According to a Novartis spokesperson, the deal launches the firm into the blood genotyping market.

Novartis said in a statement that "[a]lthough the use of molecular biology tests in transfusion compatibility testing is still at its early stages, its use is expected to become more widespread as a result of hemovigilance and transfusion safety plans being introduced in many countries."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.